Octant Scores $80M in Series B Funds, Partnership with BMS

April 21, 2022

Study will evaluate the safety, tolerability and pharmacokinetics (PK) of OCT-980 in healthy volunteers

Initiation of the study marks Octant’s transition to a clinical-stage company

Download resourceBack to all News